| Targeting HER2 in breast cancer: latest developments on treatment sequencing and the introduction of biosimilars ME Tesch, KA Gelmon Drugs 80 (17), 1811-1830, 2020 | 33 | 2020 |
| Treatment of breast cancer in young adults ME Tesch, AH Partridge American Society of Clinical Oncology Educational Book 42, 795-806, 2022 | 21 | 2022 |
| Implications of oncology trial design and uncertainties in efficacy-safety data on health technology assessments D Trapani, K Tay-Teo, ME Tesch, F Roitberg, M Sengar, SC Altuna, ... Current Oncology 29 (8), 5774-5791, 2022 | 14 | 2022 |
| Concurrent germline and somatic pathogenic BAP1 variants in a patient with metastatic bladder cancer ME Tesch, JA Pater, G Vandekerkhove, G Wang, K Binnington, AI So, ... NPJ genomic medicine 5 (1), 12, 2020 | 14 | 2020 |
| Impact of TAILORx on chemotherapy prescribing and 21‐gene recurrence score–guided treatment costs in a population‐based cohort of patients with breast cancer ME Tesch, C Speers, RM Diocee, L Gondara, SJ Peacock, A Nichol, ... Cancer 128 (4), 665-674, 2022 | 11 | 2022 |
| Engaging medical trainees in resource stewardship through resident-led teaching sessions: A choosing wisely educational initiative C Bal, ME Tesch, G Blair, O Ostrow, L Premji Canadian Medical Education Journal 12 (1), e98-e100, 2021 | 6 | 2021 |
| Screening for new primary cancers in patients with metastatic breast cancer: a provincial analysis of the Choosing Wisely Canada recommendations M Tesch, K Laing Current Oncology 26 (3), 309-313, 2019 | 5 | 2019 |
| Risk of recurrence and pregnancy outcomes in young women with breast cancer who do and do not undergo fertility preservation Y Wang, ME Tesch, C Lim, YH Xu, S Lee, K Perdizet, D Yokom, E Warner, ... Breast Cancer Research and Treatment 195 (2), 201-208, 2022 | 4 | 2022 |
| Impact of sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy on pathologic complete response rate in HER2-negative breast cancer patients ME Tesch, SK Chia, CE Simmons, N LeVasseur Breast Cancer Research and Treatment 187, 167-176, 2021 | 4 | 2021 |
| Association of tumor-infiltrating lymphocytes (TILs) with clinicopathologic characteristics and prognosis in young women with HR+/HER2-breast cancer (BC). ME Tesch, YD Guzman Arocho, LC Collins, J Heng, Y Zheng, N Tayob, ... Journal of Clinical Oncology 41 (16_suppl), 505-505, 2023 | 2 | 2023 |
| Clinicopathologic features, treatment patterns, and disease outcomes in a modern, prospective cohort of young women diagnosed with ductal carcinoma in situ ME Tesch, SM Rosenberg, LC Collins, JS Wong, L Dominici, KJ Ruddy, ... Annals of surgical oncology 29 (13), 8048-8057, 2022 | 2 | 2022 |
| Precision medicine in extended adjuvant endocrine therapy for breast cancer ME Tesch Current Opinion in Oncology 35 (6), 453-460, 2023 | 1 | 2023 |
| Estradiol (E2) levels in premenopausal women with hormone receptor-positive (HR+) breast cancer (BC) on ovarian function suppression (OFS) with gonadotropin-releasing hormone … ME Tesch, Y Zheng, SM Rosenberg, PD Poorvu, KJ Ruddy, R Tamimi, ... Journal of Clinical Oncology 40 (16_suppl), 524-524, 2022 | 1 | 2022 |
| Screening for new primary cancers in patients with metastatic breast cancer: A provincial analysis of the Choosing Wisely Canada recommendations. ME Tesch, KE Laing Journal of Clinical Oncology 36 (15_suppl), e18817-e18817, 2018 | 1 | 2018 |
| Abstract PO1-03-08: Association of patient-reported triple-negative breast cancer (TNBC) knowledge with clinical trial participation M Tesch, N Graham, S Ryan, M Hughes, E Wrabel, N Tung, S Lo, T Fynan, ... Cancer Research 84 (9_Supplement), PO1-03-08-PO1-03-08, 2024 | | 2024 |
| Using blood wisely in oncology patients: An institutional experience implementing Choosing Wisely Canada restrictive transfusion practices. M Alghawas, AS Gerrie, ME Tesch JCO Oncology Practice 19 (11_suppl), 382-382, 2023 | | 2023 |
| Duration of endocrine treatment for DCIS impacts second events: Insights from a large registry of cases at two academic medical centers. ME Tesch, JS Wong, L Dominici, KJ Ruddy, R Tamini, L Schapira, ... CANCER PREVENTION RESEARCH 15 (12), 7-8, 2022 | | 2022 |
| Abstract PR009: Breast cancer (BC) risk reduction in young women with ductal carcinoma in situ (DCIS) ME Tesch, JS Wong, L Dominici, KJ Ruddy, R Tamini, L Schapira, ... Cancer Prevention Research 15 (12_Supplement_1), PR009-PR009, 2022 | | 2022 |
| ASO Visual Abstract: Clinicopathologic Features, Treatment Patterns, and Disease Outcomes in a Modern, Prospective Cohort of Young Women Diagnosed with Ductal Carcinoma In Situ ME Tesch, SM Rosenberg, LC Collins, JS Wong, L Dominici, KJ Ruddy, ... Annals of surgical oncology 29 (13), 8058-8059, 2022 | | 2022 |
| Impact of ovarian stimulation for fertility preservation in young women with breast cancer: Updated survival and pregnancy outcomes ME Tesch, Y Wang, C Lim, YH Xu, S Lee, K Perdrizet, D Yokom, E Warner, ... CANCER RESEARCH 82 (4), 2022 | | 2022 |
Ann PartridgeDana-Farber Cancer InstituteVerified email at dfci.harvard.edu
